NEW YORK (Reuters Health) – Pfizer Inc. said on Monday that the US Food and Drug Administration (FDA) has approved the company's oral antibiotic Zithromax (azithromycin) as both a single-dose and three-day regimen for the treatment of pediatric middle ear infections.
Previously, the drug was approved as a once-daily five-day regimen for the infections.
The company noted that the single-dose regimen is not only effective, but also helps with patient compliance.
Pfizer said it expects to introduce Zithromax as a single-dose regimen early next year.
During late-day trading on the New York Stock Exchange, shares of the New York City-based firm were up 1.44 at 40.88.